Open Payments

Holy Cross Hospital

Type
Teaching hospital
Where
Silver Spring, MD
Medicare CCN
210004
Received
$392,368 in 25 records, 2024 ($1,023 general, $391,345 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2024General payment2$1,023
2024Research payment23$391,345

By company

CompanyRecordsAmountYears
AstraZeneca Pharmaceuticals LP8$288,1752024
Daiichi Sankyo Inc.3$55,2432024
ABBVIE INC.1$27,2402024
Medtronic, Inc.7$8,4572024
GlaxoSmithKline, LLC.2$7,8522024
AstraZeneca UK Limited2$4,3762024
Cochlear Americas1$9732024
Abbott Laboratories1$502024

By nature of payment

NatureRecordsAmount
Research payment23$391,345
Long term medical supply or device loan1$973
Space rental or facility fees (teaching hospital only)1$50

Records

DateCompanyAmountNatureFormProductStudyYear
2024-12-31AstraZeneca Pharmaceuticals LP$187Research paymentIn-kind items and servicesIMFINZI Biological, OncologyA Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for t2024
2024-12-31AstraZeneca UK Limited$98Research paymentIn-kind items and servicesTAGRISSO Drug, OncologyA Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Platinum Plus Pemetrexed Chemotherapy Plus Osimertini2024
2024-12-12Daiichi Sankyo Inc.$1,132Research paymentCash or cash equivalentDS8201-A-U3052024
2024-12-11Cochlear Americas$973Long term medical supply or device loanIn-kind items and servicesCOCHLEAR NUCLEUS CI632 COCHLEAR IMPLANT WITH SLIM MODIOLAR ELECTRODE Device, Implantable hearing solution2024
2024-12-09ABBVIE INC.$27,240Research paymentCash or cash equivalentA Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants Wit2024
2024-12-05AstraZeneca UK Limited$4,278Research paymentCash or cash equivalentA Phase III,Open label,Randomised,Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Ad2024
2024-12-05GlaxoSmithKline, LLC.$1,970Research paymentCash or cash equivalentA PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S2024
2024-11-07Medtronic, Inc.$416Research paymentCash or cash equivalentSYNCHROMEDII Device, Drug Infusion SystemsPSR-TDD2024
2024-08-26Medtronic, Inc.$1,029Research paymentCash or cash equivalentSYNCHROMEDII Device, Drug Infusion SystemsPSR-TDD2024
2024-08-26Medtronic, Inc.$397Research paymentCash or cash equivalentINTELLIS ADAPTIVESTIM Device, Spinal Cord NeurostimulationPSR-PSTM2024
2024-08-08Daiichi Sankyo Inc.$26,521Research paymentCash or cash equivalentDS8201-A-U3052024
2024-05-16Medtronic, Inc.$1,831Research paymentCash or cash equivalentSYNCHROMEDII Device, Drug Infusion SystemsPSR-TDD2024
2024-05-16Medtronic, Inc.$919Research paymentCash or cash equivalentINTELLIS ADAPTIVESTIM Device, Spinal Cord NeurostimulationPSR-PSTM2024
2024-04-26AstraZeneca Pharmaceuticals LP$5,352Research paymentCash or cash equivalentIMFINZI Biological, OncologyA Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durva2024
2024-04-05AstraZeneca Pharmaceuticals LP$29,880Research paymentCash or cash equivalentIMFINZI Biological, OncologyA Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Ste2024
2024-04-01Abbott Laboratories$50Space rental or facility fees (teaching hospital only)Cash or cash equivalentAMPLATZER Device, Structural Heart2024
2024-03-29Daiichi Sankyo Inc.$27,589Research paymentCash or cash equivalentDS8201-A-U3052024
2024-03-25GlaxoSmithKline, LLC.$5,882Research paymentCash or cash equivalentA PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S2024
2024-03-13AstraZeneca Pharmaceuticals LP$13,260Research paymentCash or cash equivalentIMFINZI Biological, OncologyThis is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the effica2024
2024-02-15Medtronic, Inc.$2,667Research paymentCash or cash equivalentSYNCHROMEDII Device, Drug Infusion SystemsPSR-TDD2024
2024-02-15Medtronic, Inc.$1,196Research paymentCash or cash equivalentINTELLIS ADAPTIVESTIM Device, Spinal Cord NeurostimulationPSR-PSTM2024
2024-01-24AstraZeneca Pharmaceuticals LP$187,152Research paymentCash or cash equivalentENHERTU Biological, OncologyAn open-label, randomized, multicenter, Phase 3 study to assess the efficacy and safety of Trastuzumab Deruxtecan as fir2024
2024-01-19AstraZeneca Pharmaceuticals LP$19,132Research paymentCash or cash equivalentTruqap Drug, OncologyA Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo 2024
2024-01-17AstraZeneca Pharmaceuticals LP$1,250Research paymentCash or cash equivalentIMFINZI Biological, OncologyA Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for t2024
2024-01-05AstraZeneca Pharmaceuticals LP$31,960Research paymentCash or cash equivalentA Phase III, Multicentre, Randomised, Double blind, Parallel group, Placebo controlled Study to Evaluate the Efficacy an2024

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Montgomery CountySilver Spring CDP

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Silver Spring, MD, county Montgomery County, MD, state Maryland; placed by its city name.

MeasurePlace (city or town)
Silver Spring, MD
County
Montgomery County, MD
State
Maryland
Population B0100381,4621,065,9496,206,011
Population, 2020 census P181,0151,062,0616,177,224
Median age B0100235.640.239.4
Under 18 B0100122.2%22.8%22.2%
65 and over B0100112.1%17.0%16.7%
Households B1100133,988389,2102,362,928
Foreign born B0500233.9%33.6%16.6%
Median household income B19013$99,860$132,450$103,678
Median family income B19113$126,101$164,096$127,817
Per capita income B19301$57,635$67,571$52,979
Poverty rate B1700110.6%7.5%9.4%
Unemployment rate B230255.4%4.9%4.9%
Civilian labor force B2302550,814590,7763,313,651
Mean commute (minutes) B0801334.031.931.1
Bachelor's degree or higher B1500360.6%60.6%43.4%
Housing units B2500135,774406,5312,560,784
Owner-occupied B2500338.3%65.3%67.6%
Renters B2500361.7%34.7%32.4%
Median home value B25077$643,300$640,300$419,900
Median gross rent B25064$1,913$2,068$1,705
White, not Hispanic B0300232.8%39.5%46.6%
Black B0300228.3%18.3%28.9%
Hispanic or Latino B0300224.5%21.0%12.5%
Asian B030028.5%15.3%6.5%
American Indian and Alaska Native B030020.1%0.1%0.1%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Silver Spring, MD.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.